ArticleBulletin of experimental biology and medicine2025
Effect of Tobramycin on the Biofilm-Forming Forms of Pseudomonas aeruginosa Isolates Isolated from Patients with Cystic Fibrosis.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biological properties of nine clinical isolates of Pseudomonas aeruginosa obtained from five patients with cystic fibrosis were assessed. Six different sequence types of P. aeruginosa with different biofilm-forming abilities were detected. It was found that at the initial stage of adhesion, four isolates were tobramycin-resistant, while in the formed biofilm, almost 100% survival was recorded. The properties of the isolates were associated with the sequence type: when it changed, the biofilm-forming ability decreased, but the number of viable cells resistant to tobramycin at a concentration of 2 μg/ml increased. The study shows that the existence of a biofilm is a key factor ensuring, despite constant antimicrobial therapy, the long-term persistence of P. aeruginosa in patients with cystic fibrosis.
Indexed as
Identifiers
41188565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.